ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
October 14, 2020 16:25 ET
|
ALX Oncology
BURLINGAME, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
October 06, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that...
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer
September 22, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ALX Oncology (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today...
ALX Oncology Added to Russell 2000® and 3000® Indexes
September 17, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
ALX Oncology Announces Participation at Upcoming Investor Conferences
September 08, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights
August 27, 2020 16:05 ET
|
ALX Oncology
Completed initial public offering of common stock on July 21, 2020, raising gross proceeds of $185.7 million Strengthened leadership team and expanded board of directors to support growth IND open...
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 21, 2020 16:05 ET
|
ALX Oncology
BURLINGAME, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,...
ALX Oncology Announces Pricing of Initial Public Offering
July 16, 2020 20:38 ET
|
ALX Oncology
BURLINGAME, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,...